pharma is the sole category represented across all 1 tracked stories. AlpE is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 2 original sources each. BioVersys AG appears in 1 tracked Biotech story from March 18, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about BioVersys AG
pharma is the sole category represented across all 1 tracked stories. AlpE is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 2 original sources each. BioVersys AG appears in 1 tracked Biotech story from March 18, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 18 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering BioVersys AG. Shared-story counts are live from our verified record — not editorial picks.
BioVersys AG reported its full-year 2025 financial results, highlighting the successful transition of its lead candidate AlpE into Phase 2b clinical trials for pulmonary tuberculosis. The company's progress underscores its leadership in the antimicrobial resistance (AMR) space as it moves toward late-stage clinical validation.
BioVersys AG is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.